XML 51 R62.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2010
Mar. 31, 2010
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Alliances and Collaborations Statement [Line Items]                      
Net sales $ 5,454 $ 5,345 $ 5,434 $ 5,011 $ 5,111 $ 4,798 $ 4,768 $ 4,807 $ 21,244 $ 19,484 $ 18,808
Amortization expense - upfront, milestone and other licensing payments                 (271) (199) (170)
Other (income)/expense                 (169) 126 (381)
Other intangible assets - upfront, milestone and other licensing payments 3,124       3,370       3,124 3,370  
ERBITUX [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Net sales                 691 662 683
Lilly [Member] | ERBITUX [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Net sales                 691 662 683
Lilly [Member] | ERBITUX [Member] | North America [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Distribution fee, percentage of net sales 39.00%               39.00%    
Distribution fees and royalty expense                 287 275 279
Lilly [Member] | ERBITUX [Member] | Japan [Member] | Commercialization fee [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Other (income)/expense                 (34) (39) (28)
Lilly [Member] | necitumumab [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Research and development reimbursements to/(from) collaboration partner                 12 12 5
Lilly [Member] | necitumumab [Member] | Pre-commercialization [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Number of months of advance notice to terminate collaboration 12               12    
Lilly [Member] | necitumumab [Member] | Post-commercialization [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Number of months of advance notice to terminate collaboration 18               18    
Lilly [Member] | necitumumab [Member] | United States and Canada [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Percentage selling effort provided by collaboration partner 50.00%               50.00%    
Percentage of profit loss from collaboration 55.00%               55.00%    
Lilly [Member] | necitumumab [Member] | United States [Member] | Upfront, milestone and other licensing payments [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Milestone payment upon approval 250               250    
Lilly [Member] | necitumumab [Member] | Development Costs For United States Studies [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Funding of development costs, percentage 55.00%               55.00%    
Lilly [Member] | necitumumab [Member] | Development Costs For Global Studies [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Funding of development costs, percentage 27.50%               27.50%    
Lilly [Member] | necitumumab [Member] | Development Costs For Japan Studies [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Funding of development costs, percentage 50.00%               50.00%    
Lilly [Member] | ERBITUX And Necitumumab [Member] | Upfront, milestone and other licensing payments [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Amortization expense - upfront, milestone and other licensing payments                 37 37 37
Other intangible assets - upfront, milestone and other licensing payments 249       286       249 286  
Payment for license acquisition $ 500               $ 500    
Lilly and Merck KGaA [Member] | ERBITUX [Member] | Japan [Member]
                     
Alliances and Collaborations Statement [Line Items]                      
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner. 50.00%               50.00%